Table of contents
- Trial overview
- Who can join the study
- Study design and phase
- What is being measured
- Trial status and size
- What the study means for patients
Trial overview
The trial with ID 2024-516284-90-00 is a Phase 3 study of SODIUM SULFIDE NONAHYDRATE, given as a nasal spray in a pressurized container, compared with placebo.[1] It is designed to test whether the study spray helps people with acute rhinitis, rhinopharyngitis, and rhinosinusitis that do not require antibiotic therapy.[1]
The brief summary says the main purpose is to evaluate the effectiveness of Actisoufre nasal spray in adults and children over 6 years old.[1] The study is interventional, which means participants receive a study treatment rather than only being observed.[1]
Who can join the study
This study includes female and male adult and paediatric participants over 6 years of age.[1] “Paediatric” means children and adolescents.[1]
People must have acute rhinitis, rhinopharyngitis, or rhinosinusitis, and their illness must not need antibiotic therapy.[1] In simple terms, the study is for common short-term nose and throat infections or inflammation where antibiotics are not considered necessary.[1]
Study design and phase
This is a prospective, controlled, randomized, double blind, two-arm, parallel-group, multicentre study.[1] “Prospective” means the study follows people forward in time after they join.[1] “Randomized” means treatment is assigned by chance, and “double blind” means neither the participants nor the study team knows who receives the study spray or placebo.[1]
“Two-arm” means there are two groups in the study, and “parallel-group” means the groups are followed at the same time.[1] “Multicentre” means the study is run at more than one site.[1]
The phase is Phase 3, which is usually used to confirm how well a treatment works in a larger group of patients and to continue safety monitoring.[1]
What is being measured
The main outcome is the change in nasal symptoms from baseline to Day 4, measured with the Common Cold Symptoms Severity Questionnaire.[1] Baseline means the starting point before treatment effects are measured.[1]
The symptoms being tracked are nasal obstruction, rhinorrhea, thick mucus, sneezing, and cough.[1] Rhinorrhea means a runny nose or drainage from the nose.[1]
The questionnaire is used at Baseline, Day 2, Day 3, Day 4, and Day 8, so researchers can see how symptoms change over time.[1]
Trial status and size
The trial status is Authorised.[1] The planned enrollment is 248 participants.[1]
The study compares the Actisoufre nasal spray with placebo, which helps researchers judge whether any symptom improvement is linked to the study treatment rather than chance alone.[1]
What the study means for patients
For patients, this trial is looking at a short course of nasal spray treatment for common nose and throat inflammation that does not need antibiotics.[1] The study focuses on practical symptoms that matter in daily life, such as blocked nose, runny nose, mucus, sneezing, and cough.[1]
Because the trial is randomized and double blind, the results are intended to be fair and less biased.[1] The main question is whether SODIUM SULFIDE NONAHYDRATE can improve symptoms better than placebo in this patient group.[1]



